


PHARMACEUTICAL 2021

CTI BIOPHARMA CORP Rank 258 of 402







PHARMACEUTICAL 2021

CTI BIOPHARMA CORP Rank 258 of 402



The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Net Income, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 43%, being 4.5% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	54,325
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,038
Liabilities, Non-Current	1,174
Other Assets	3,197
Other Compr. Net Income	2.0
Other Expenses	4,200
Other Liabilities	0
Other Net Income	-4,682
Other Revenues	0
Property and Equipment	719
Research and Development	25,943
Selling, General and Administrative Expense	17,626

Output Variable	Value in 1000 USD
Assets	58,241
Liabilities	18,212
Expenses	47,769
Revenues	0
Stockholders Equity	40,029
Net Income	-52,451
Comprehensive Net Income	-52,450
Economic Capital Ratio	43%

